Wolverine Asset Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Wolverine Asset Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,600	Closed	-$131K	–	2563
2021 Q3	$131K	Hold	21,600	–	–	﹤0.01%	1244
2021 Q2	$177K	Hold	21,600	–	–	﹤0.01%	1296
2021 Q1	$193K	Sell	21,600 -300	-1%	-$3.44K	﹤0.01%	1246
2020 Q4	$252K	Hold	21,900	–	–	﹤0.01%	1038
2020 Q3	$227K	Buy	21,900 +7,500	+52%	+$91.9K	﹤0.01%	947
2020 Q2	$189K	Buy	14,400 +13,900	+2,780%	+$144K	﹤0.01%	949
2020 Q1	$3K	Sell	500 -2,500	-83%	-$37.7K	﹤0.01%	1394
2019 Q4	$62K	Buy	3,000 +500	+20%	+$8.43K	﹤0.01%	1163
2019 Q3	$34K	Buy	+2,500	New	+$29.7K	﹤0.01%	1248

Wolverine Asset Management's FLXN Position: Q3 2021 in Review

Wolverine Asset Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 7,747 shares — an estimated $48.3K sold.

Wolverine Asset Management first reported a position in FLXN in Q1 2020 and held it in 3 quarters. The position peaked at $63K in Q2 2021. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

Wolverine Asset Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
Wolverine Asset Management sold 7,747 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $48.3K.
Wolverine Asset Management first reported a position in Flexion Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
Wolverine Asset Management's Flexion Therapeutics, Inc. position peaked at $63K in Q2 2021.
145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.